Replimune Group (NASDAQ:REPL) Trading Down 6.7% on Insider Selling

Replimune Group, Inc. (NASDAQ:REPL) shares were down 6.7% on Tuesday after an insider sold shares in the company. The company traded as low as $8.04 and last traded at $7.9650. Approximately 678,276 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 1,477,915 shares. The stock had previously closed at $8.54.

Specifically, insider Christopher Sarchi sold 6,500 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the completion of the sale, the insider directly owned 151,588 shares in the company, valued at $1,214,219.88. This represents a 4.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

Several analysts recently weighed in on REPL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Piper Sandler upped their price objective on Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Wedbush upped their price objective on Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.00.

Replimune Group Trading Down 8.7%

The business has a fifty day simple moving average of $7.62 and a 200-day simple moving average of $7.92. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The firm has a market cap of $644.05 million, a price-to-earnings ratio of -2.27 and a beta of 0.74.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. As a group, equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in Replimune Group in the 4th quarter worth about $29,000. CWM LLC increased its stake in shares of Replimune Group by 248.6% in the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after buying an additional 2,886 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after buying an additional 1,879 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Replimune Group in the second quarter valued at about $69,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after buying an additional 7,569 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.